Molecular Signatures of Cutaneous Dupilumab Response

NCT05858619 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab

Sponsor

University of California, San Francisco